ArticleRMD open2021
Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy.
Article in RMD open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Early prediction of joint space narrowing in rheumatoid arthritis using AI-quantified bilateral joint space asymmetry on hand radiography.Japanese journal of radiology · 2026Article
- EULAR-OMERACT consensus-based scoring system for synovitis 10 years later: a validated tool for routine care and clinical trials.RMD open · 2026Review
- Imaging in clinical trials of rheumatoid arthritis: where are we in 2025?Skeletal radiology · 2025Review
- Early rheumatoid arthritis, two distinctive structural damage patterns revealed by MRI: an 8-year longitudinal study.European radiology · 2025Article
- Integrating Bibliometrics and Bioinformatics to Map Knowledge Structure and Trend Synthesis in Rheumatoid Arthritis and Bone Erosion (2015-2024).Journal of multidisciplinary healthcare · 2025Article
- Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update.Rheumatology and immunology research · 2024Article
- RANet: a custom CNN model and quanvolutional neural network for the automated detection of rheumatoid arthritis in hand thermal images.Scientific reports · 2023Article
- Clinical prediction models of rheumatoid arthritis and its complications: focus on cardiovascular disease and interstitial lung disease.Arthritis research & therapy · 2023Review
- Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.Rheumatology (Oxford, England) · 2023Article
- Article
- Importance of baseline musculoskeletal ultrasound findings in the prognosis of rheumatoid arthritis.Clinical rheumatology · 2022Article
- The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings.Frontiers in immunology · 2022Article
- ROCK inhibition with Y-27632 reduces joint inflammation and damage in serum-induced arthritis model and decreasesFrontiers in immunology · 2022Article
- Rheumatoid Arthritis Relapse and Remission - Advancing Our Predictive Capability Using Modern Imaging.Journal of inflammation research · 2021Review
- The Clinical Utility of Musculoskeletal Ultrasound for Disease Activity Evaluation and Therapeutic Response Prediction in Rheumatoid Arthritis Patients: A Narrative Review.Journal of medical ultrasoundReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate if inflammation detected by MRI or ultrasound at rheumatoid arthritis (RA) onset is predictive of erosive progression or poor response to methotrexate monotherapy, and to investigate if subclinical inflammation in remission is predictive of future treatment escalation or erosive progression.
methodsIn a 2-year study, 218 patients with disease-modifying antirheumatic drug-naïve early RA were treated by a tight-control treat-to-target strategy corresponding to current recommendations. MRI and ultrasound were performed at regular intervals. Baseline imaging-based inflammation measures were analysed as predictors for early methotrexate failure and erosive progression using univariate and multivariate regression adjusted for clinical, laboratory and radiographic measures. In patients in remission after 1 year, imaging measures were analysed as predictors of treatment escalation and erosive progression during the second year. The added value of imaging in prediction models was assessed using receiver operating characteristic analyses.
resultsBaseline MRI inflammation was associated with MRI erosive progression and ultrasound with radiographic erosive progression. No imaging inflammation measure was associated with early methotrexate failure. Imaging inflammation was present in a majority of patients in clinical remission. Tenosynovitis was associated with treatment escalation, and synovitis and tenosynovitis with MRI/radiographic erosive progression during the second year. Imaging information did not improve prediction models for any of the outcomes.
conclusionsImaging-detected inflammation, both at diagnosis and in remission, is associated with elements of future disease development. However, the lack of a significant effect on prediction models indicates limited value of systematic MRI and ultrasound in management of early RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.